For the third quarter of 2026, analysts anticipate Compass Therapeutics will report a consensus revenue of $0.23 million and an earnings per share loss of $0.12, with the stock currently trading at $0.80 compared to a consensus price target of $5.83.

The primary story for investors is the company's regulatory strategy for its lead oncology candidate, tovecimig, following the FDA's recommendation for an additional survival-benefit trial before a BLA submission.

Despite this feedback, management plans to move forward with the filing based on positive Phase 2/3 ORR and PFS results from the COMPANION-002 study. Investors are also closely monitoring the company's cash position, which was last reported at $180 million, providing a projected runway into 2028.